Juan C Varela
Overview
Explore the profile of Juan C Varela including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
259
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Linhares Y, Freytes C, Cherry M, Bachier C, Maris M, Hoda D, et al.
Blood Adv
. 2024 Sep;
8(23):6114-6126.
PMID: 39347584
Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB chimeric antigen receptor (CAR) T-cell product approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We present the OUTREACH primary analysis, evaluating the...
2.
Hantel A, Brunner A, Plascak J, Uno H, Varela J, Luskin M, et al.
J Natl Cancer Inst
. 2024 Mar;
116(7):1178-1184.
PMID: 38518098
Background: Clinical trial participation at Comprehensive Cancer Centers (CCC) is inequitable for minoritized racial and ethnic groups with acute leukemia. CCCs care for a high proportion of adults with acute...
3.
Hoffmann M, Hunter B, Cobb P, Varela J, Munoz J
Transplant Cell Ther
. 2023 Apr;
29(7):440-448.
PMID: 37031747
Diffuse large B cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin lymphoma. Although outcomes to frontline therapy are encouraging, patients who are refractory to or in relapse after...
4.
Yu J, Diaz J, Goldstein S, Patel R, Varela J, Reyenga C, et al.
Transplant Cell Ther
. 2021 Apr;
27(6):500.e1-500.e6.
PMID: 33849818
Infections in adult patients with hematological malignancies (HM) and stem cell transplant (SCT) recipients are a significant cause of morbidity and mortality. A timely diagnosis of infections can have a...
5.
Yuan C, Boyd A, Nelson J, Patel R, Varela J, Goldstein S, et al.
Biol Blood Marrow Transplant
. 2019 Feb;
25(7):1320-1324.
PMID: 30710685
Thrombocytopenia after allogeneic hematopoietic stem cell transplantation (allo-SCT) can pose significant problems in management of patients. Eltrombopag is a small-molecule thrombopoietin receptor agonist that has been approved for use in...
6.
Neal L, Bailey S, Wyatt M, Bowers J, Majchrzak K, Nelson M, et al.
J Immunol Res Ther
. 2017 Aug;
2(1):68-79.
PMID: 28825053
Adoptive T cell transfer (ACT) can mediate objective responses in patients with advanced malignancies. There have been major advances in this field, including the optimization of the generation of tumor-reactive...
7.
Majchrzak K, Nelson M, Bowers J, Bailey S, Wyatt M, Wrangle J, et al.
JCI Insight
. 2017 Apr;
2(8).
PMID: 28422756
ICOS costimulation generates Th17 cells with durable memory responses to tumor. Herein, we found that ICOS induces PI3K/p110δ/Akt and Wnt/β-catenin pathways in Th17 cells. Coinhibiting PI3Kδ and β-catenin altered the...
8.
Schlosser R, Mulligan R, Casey S, Varela J, Harvey R, Atkinson C
Am J Rhinol Allergy
. 2010 Jan;
24(1):21-5.
PMID: 20109314
Background: The complement cascade forms part of the initial innate response to pathogens in the airway. Complement activation is important in the maintenance of host homeostasis, but excessive and uncontrolled...
9.
Atkinson C, Varela J, Tomlinson S
Circ Res
. 2009 Oct;
105(11):1094-101.
PMID: 19815824
Rationale: Donor brain death (BD) is an unavoidable occurrence in heart transplantation and results in profound physiological derangements that render the heart more susceptible to ischemia/reperfusion injury in the recipient...
10.
Varela J, Imai M, Atkinson C, Ohta R, Rapisardo M, Tomlinson S
Cancer Res
. 2008 Aug;
68(16):6734-42.
PMID: 18701498
Complement-inhibitory proteins expressed on cancer cells can provide protection from antitumor antibodies and may potentially modulate the induction of an immune response to tumor-associated antigens. In the current study, we...